MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

AdaptHealth Corp

Slēgts

SektorsVeselības aprūpe

12.66 0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.44

Max

12.84

Galvenie mērījumi

By Trading Economics

Ienākumi

-124M

-102M

Pārdošana

26M

846M

P/E

Sektora vidējais

17.527

63.808

Peļņas marža

-11.998

Darbinieki

10,900

EBITDA

-147M

24M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+0.4% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

281M

1.7B

Iepriekšējā atvēršanas cena

12.02

Iepriekšējā slēgšanas cena

12.66

Ziņu noskaņojums

By Acuity

43%

57%

99 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

AdaptHealth Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. apr. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

2026. g. 17. apr. 18:15 UTC

Galvenie ziņu notikumi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 17. apr. 16:49 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

2026. g. 17. apr. 20:11 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Buy Neurona Therapeutics for Up to $1.15B

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 17. apr. 19:34 UTC

Tirgus saruna
Peļņas
Iegādes, apvienošanās, pārņemšana

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

2026. g. 17. apr. 19:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

2026. g. 17. apr. 19:26 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up -- Market Talk

2026. g. 17. apr. 19:21 UTC

Tirgus saruna

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

2026. g. 17. apr. 19:15 UTC

Tirgus saruna

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

2026. g. 17. apr. 19:07 UTC

Tirgus saruna

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

2026. g. 17. apr. 18:57 UTC

Galvenie ziņu notikumi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

2026. g. 17. apr. 18:53 UTC

Iegādes, apvienošanās, pārņemšana

UCB 2026 Rev Guidance Unchanged

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

2026. g. 17. apr. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

2026. g. 17. apr. 18:14 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

2026. g. 17. apr. 18:00 UTC

Galvenie ziņu notikumi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

2026. g. 17. apr. 17:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

2026. g. 17. apr. 17:26 UTC

Tirgus saruna
Peļņas

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Salīdzinājums

Cenas izmaiņa

AdaptHealth Corp Prognoze

Cenas mērķis

By TipRanks

0.4% augšup

Prognoze 12 mēnešiem

Vidējais 12.63 USD  0.4%

Augstākais 14 USD

Zemākais 9.5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AdaptHealth Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

3

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

7.95 / 8.505Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

99 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AdaptHealth Corp

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat